Alternate site health provider Option Care Health (NASDAQ: OPCH) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 12.2% year on year to $1.44 billion. The company expects the full year’s revenue to be around $5.63 billion, close to analysts’ estimates. Its non-GAAP profit of $0.45 per share was 4.9% above analysts’ consensus estimates.

Is now the time to buy OPCH? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Option Care Health’s third quarter results surpassed Wall Street’s revenue and profit expectations, yet the market reacted negatively, reflecting concerns highlighted by management about margin headwinds and evolving product dynamics. CEO John Rademacher cited strong double-digit growth in both acute and chronic therapies, aided by a favorable shift toward home and ambulatory care. However, management acknowledged that increased adoption of Stelara biosimilars—drugs designed to closely mimic already approved biologic therapies—reduced gross margins due to lower reimbursement rates. CFO Meenal Sethna noted that the chronic portfolio’s margin was pressured by this trend, leading to a 380 basis point negative impact.

Looking ahead, Option Care Health’s updated guidance is shaped by expectations of continued biosimilar adoption, a dynamic regulatory environment, and ongoing investments in technology and clinical programs. Management believes that further biosimilar uptake and payer-driven product shifts may create incremental revenue and gross margin headwinds. Rademacher emphasized that while these trends are “contemplated in the way that we have put the guidance forward,” the company sees opportunities to offset pressures through new therapy launches, expansion of advanced practitioner services, and deepened partnerships with pharmaceutical manufacturers and health plans.

Key Insights from Management’s Remarks

Management attributed this quarter’s performance to balanced therapy portfolio growth, shifting industry dynamics, and disciplined capital deployment amid evolving product economics.

• Therapy portfolio diversification: Growth was driven by both acute and chronic therapies, with mid-teens expansion in the acute segment and low double-digit gains in chronic therapies. Rademacher emphasized that “the breadth of the portfolio and the momentum we’re building” helped offset biosimilar-related headwinds.
• Biosimilar transition pressures: The adoption of Stelara biosimilars resulted in lower reference pricing, reducing revenue and gross profit. Sethna quantified a 380 basis point negative impact to chronic therapy growth and noted this was “contemplated in the way that we have articulated the view of the guidance.”
• Competitive landscape and market exits: Management cited further market share gains in acute therapies, partly due to competitors exiting the space. Rademacher described the company’s “national scale and local responsiveness” as key differentiators enabling Option Care Health to capture demand.
• Infusion suite and practitioner model expansion: The company continued rolling out new infusion clinics and growing its advanced practitioner model, with 24 out of 175 facilities now offering higher-acuity care. Management expects this to broaden market reach, particularly for more clinically complex patient cohorts.
• Capital allocation and technology investment: Sethna highlighted ongoing investments in technology, artificial intelligence, and enhanced analytics to drive operational efficiency. The company also completed the integration of the Intramed Plus acquisition and executed $62 million in share repurchases, while maintaining a focus on strategic tuck-in M&A.

Drivers of Future Performance

Management’s outlook centers on the impacts of biosimilar uptake, regulatory change, and investments in new clinical capabilities as primary drivers of future performance.

• Biosimilar dynamics and gross margin: The company expects continued biosimilar adoption, particularly for Stelara, to create incremental margin headwinds as lower-priced alternatives gain share. Rademacher stressed that this was factored into the latest guidance, though future impacts depend on uptake rates and payer preferences.
• Regulatory and policy environment: Sethna and Rademacher noted that ongoing changes in drug pricing policy, especially related to the Inflation Reduction Act (IRA) and potential new tariffs, could affect reimbursement rates and product economics. Management is monitoring these risks but expects limited financial impact in the near term based on current assumptions.
• Investment in technology and services: Option Care Health plans to expand its advanced practitioner model, add new infusion clinics, and invest in artificial intelligence-driven tools to enhance efficiency and patient onboarding. Management believes these initiatives can help offset industry headwinds and enable growth in higher-acuity and rare disease therapies.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will focus on (1) the pace and profitability of biosimilar adoption, especially for Stelara and other chronic therapies, (2) the continued rollout and patient uptake of advanced practitioner services and new infusion suite locations, and (3) the execution of technology-driven efficiency initiatives. We will also monitor regulatory developments and their potential impact on reimbursement and therapy mix.

Option Care Health currently trades at $25.34, down from $28.68 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free for active Edge members).

Our Favorite Stocks Right Now

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.